Back to Search Results

Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study.

Endocrinology and Nutrition Department, Hospital Universitari Arnau de Vilanova, and Obesity, Diabetes and Metabolism Research Group, Institut de Recerca Biomèdica de Lleida, Universitat de Lleida. Lleida, Spain. Endocrinology and Nutrition Department. Hospital Universitari Vall d'Hebron, and Diabetes and Metabolism Research Unit, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. Endocrinology and Nutrition Department, Hospital Universitario Virgen de la Victoria de Málaga, Institute of Biomedical Research of Malaga, University of Malaga, Málaga, Spain. Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. Respiratory Department, Hospital Universitari Arnau de Vilanova-Santa María, and Translational Research in Respiratory Medicine, Institut de Recerca Biomèdica de Lleida, Universitat de Lleida. Lleida, Spain. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Endocrinology and Nutrition Department, Hospital Universitario A Coruña, A Coruña, Spain. Department of Endocrinology and Nutrition, Hospital Universitari Germans Trias i Pujol, Germans Trias i Pujol Research Institute, Badalona, Spain.

Diabetes. 2022;(2):315-320
Full text from:

Other resources

Abstract

To evaluate the effect of liraglutide, a glucagon-like peptide 1 receptor agonist, on pulmonary function and serum levels of surfactant protein D (SP-D) in type 2 diabetes. A double-blind, randomized, crossover, placebo-controlled clinical trial comprising 76 patients with a baseline forced expiratory volume in 1 s <90% of that predicted. Liraglutide was administered for 7 weeks (2 weeks of titration plus 5 weeks at 1.8 mg daily). This short duration was intentional to minimize weight loss as a potential confounding factor. Serum level of SP-D was used as a biomarker of alveolar-capillary barrier integrity. Liraglutide exerted a positive impact on forced vital capacity (FVC) in comparison with placebo (ΔFVC 5.2% of predicted [from 0.8 to 9.6]; P = 0.009). No differences in the other pulmonary variables were observed. Participants under liraglutide treatment also experienced a decrease in serum SP-D (P = 0.038). The absolute change in FVC correlated with final serum SP-D in participants receiving liraglutide (r = -0.313, P = 0.036). Stepwise multivariate regression analysis showed that final serum SP-D independently predicted changes in FVC. In conclusion, liraglutide increased FVC in patients with type 2 diabetes. This effect was associated with a significant decrease of circulating SP-D, thus pointing to a beneficial effect in the alveolar-capillary function.

Methodological quality

Metadata

MeSH terms : Liraglutide